... on the target tissue and hormonal milieu. The mechanisms by which SERMs elicit tissue-specific responses are being intensively investigated, and recently a novel pathway for estrogen receptor-mediated gene activation by the SERM raloxifene has been demonstrated. The tissue-specific activity of SERMs suggests...

... of bone turnover include bisphosphonate, hormone replacement therapy (HRT) and raloxifene. Anabolic drugs that stimulate the rate of bone formation include parathyroid hormone and its 1–34 amino acid peptide, teriparatide. Some drugs such as strontium ranelate fall into a third category. They have weak...

... to this adverse event profile. Raloxifene binds to the oestrogen receptor, like the oestrogen in HRT, but in some tissues it acts as an oestrogen agonist and in others as an oestrogen antagonist. Long-term treatment results in a decrease in the risk of vertebral fractures but not in the risk of non...